替尔泊肽(Tirzepatide) - 药物靶点：GIPR x GLP-1R_在研适应症：阻塞性睡眠呼吸暂停综合征，肥胖，超重_专利_临床

概要

基本信息

药物类型

合成多肽

别名

Tirzepatide (USAN)、TZP、ZEHP-bownd

+ [12]

靶点

GIPR x GLP-1R

作用方式

激动剂

作用机制

GIPR激动剂(胃抑素受体激动剂)、GLP-1R激动剂(胰高血糖素样肽-1激动剂)

治疗领域

神经系统疾病内分泌与代谢疾病呼吸系统疾病+ [8]

在研适应症

阻塞性睡眠呼吸暂停综合征肥胖超重+ [14]

非在研适应症

低血糖终末期肾脏病肝损伤

原研机构

Lexaria Bioscience Corp.

Eli Lilly & Co.

在研机构

Eli Lilly & Co.Eli Lilly Nederland BV

美国礼来亚洲公司上海代表处

+ [7]

非在研机构-

权益机构

Eli Lilly Japan KK

Mitsubishi Tanabe Pharma Corp.

最高研发阶段批准上市

首次获批日期

美国 (2022-05-13),

2型糖尿病

最高研发阶段(中国)批准上市

特殊审评优先审评 (美国)、快速通道 (美国)

登录后查看时间轴

结构/序列

Sequence Code 10195070

来源: *****

关联

147

项与替尔泊肽相关的临床试验

NCT06820281

/ Not yet recruiting临床2期IIT

Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes: a Phase 2 Double Blinded Placebo Controlled Clinical Trial (TIRTLE2)

This study will examine the effects of Tirzepatide (TZP), a glucagon-like peptide 1 (GLP1) - gastric inhibitory peptide (GIP) co-agonist, on metabolism in type 1 diabetes (T1D). Research participants with T1D will undergo measures of insulin sensitivity, and hormone levels post-meal, post-hypoglycemia and during the overnight period. These measures will be performed prior to, and after 4 weeks of treatment with TZP. These measures will also be compared to a group of adults without diabetes (who will not receive treatment with TZP) to assess how metabolism of energy and nutrients is different in T1D compared to people without diabetes.

开始日期2025-12-01

申办/合作机构

The Garvan Institute of Medical Research

NCT06651177

/ Not yet recruiting临床2期IIT

NIDA CTN-0152: Evaluation of Tirzepatide As an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder: a Pragmatic, Multi-site, Double-blind, Randomized, Placebo-controlled Trial (TAB)

The primary objective of this research study is to evaluate the effect of tirzepatide, relative to placebo, as an adjunct to BUP on retention, substance use, and sleep outcomes in individuals with OUD.

开始日期2025-09-16

申办/合作机构

National Institute on Drug Abuse

NCT06801015

/ Not yet recruiting临床4期IIT

A Randomized, Placebo-Controlled Trial of the Effects of Long-Acting GLP-1 or Dual Incretin (GLP-1 and GIP) Modulation on Gastric Motor Functions

The purpose of this study is to compare effects of weekly SQ semaglutide 2.4mg SQ, SQ tirzepatide 10mg, and placebo administered for 24 weeks on GES measured repeatedly at baseline, 16 weeks, 24 weeks, 28 weeks, 4 weeks after stopping the medication, and accommodation and satiation at 24 weeks compared to baseline.

开始日期2025-08-15

申办/合作机构

Mayo Clinic

100 项与替尔泊肽相关的临床结果

登录后查看更多信息

100 项与替尔泊肽相关的转化医学

登录后查看更多信息

100 项与替尔泊肽相关的专利（医药）

登录后查看更多信息

1,114

项与替尔泊肽相关的文献（医药）

2025-12-31·European Clinical Respiratory Journal

Safety and efficacy of glucagon-like peptide-1 receptor agonists in patients with obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trials

Review

作者: Balbaa, Elsayed ; Altobaishat, Obieda ; Farid Gadelmawla, Ahmed ; Turkmani, Mustafa ; Abouzid, Mohamed

Background:

Obstructive sleep apnea (OSA) is a common condition affecting around one billion people worldwide. Emerging evidence from recent studies suggests that Glucagon-like peptide 1 receptor (GLP-1) agonists may reduce OSA severity. Hence, this meta-analysis aims to evaluate the efficacy and safety of GLP-1 agonists in patients with OSA.

Methods:

Following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, we searched four electronic databases (PubMed, EMBASE, Cochrane Library, Scopus, and Web of Science) to identify eligible studies reported up to 24 June 2024. Using Review Manager software, we reported outcomes as risk ratios (RRs) or mean difference (MD) and confidence intervals (CIs). The protocol for this review has been registered and published in PROSPERO with the ID (CRD42024562853).

Results:

The meta-analysis included three randomized controlled trials with 828 patients. Pooled analysis of patients administered GLP-1 agonists or tirzepatide showed improvement in Apnea/Hypopnea Index (MD -16.57 events per hour, 95% CI [-27.41, -5.73], p = 0.003), weight reduction (MD -12.71%, 95% CI [-21.38, -4.03], p = 0.004), and systolic blood pressure (MD -4.93 mmHg,95% CI [-7.67, -2.19], p = 0.0004). Tirzepatide showed a reduction in high-sensitivity C-reactive protein (MD -0.89 mg/dl, 95% CI [-1.25, -0.54], p < 0.0001) and sleep apnea-specific hypoxic burden (MD -66.21%/min, 95% CI [-81.75, -50.67], p < 0.0001). Despite the heterogeneity observed in the AHI and weight, it was resolved, and the results were consistent. GLP-1 agonists/tirzepatide showed comparable outcomes concerning diastolic blood pressure (MD -1.34 mmHg, 95% CI [-2.80, 0.12], p = 0.07). No significant serious adverse events were observed for GLP-1 agonists/tirzepatide, but it was associated with a higher incidence of gastrointestinal adverse events.

Conclusion:

GLP-1 agonists, including tirzepatide, improved Apnea/Hypopnea Index, weight, and systolic blood pressure in adults with moderate-to-severe OSA. However, the evidence remains limited to two published studies comprising three randomized controlled trials using different pharmacological agents. Consequently, further research is needed before firm conclusions can be drawn.

2025-12-31·Journal of Pharmaceutical Policy and Practice

Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado

Article

作者: Saseen, Joseph J. ; Dardouri, Mouna ; Nair, Kavita V. ; Moore, Gina D. ; DiStefano, Michael J.

Background:

High prices and other access barriers have contributed to the rise of a market for compounded glucagon-like peptide-1 receptor agonists for weight loss in the United States. This market has not been systematically studied. We conducted a pilot study to assess the prevalence, characteristics, and advertising content of direct-to-consumer providers of compounded glucagon-like peptide-1 products for weight loss in Colorado.

Methods:

We conducted a cross-sectional study of websites advertising compounded glucagon-like peptide-1 products for weight loss in Colorado. Websites were identified using Google searches focused on census-defined statistical areas. Searches were conducted between March 21 and April 12, 2024. Data collected from websites included physical addresses, business type, highest reported staff credential, advertised glucagon-like peptide-1 products, whether businesses referred to Food and Drug Administration approval when describing products, and whether businesses referred to products as 'generic'.

Results:

We identified 93 business websites advertising compounded glucagon-like peptide-1 products for weight loss corresponding to 188 physical locations throughout Colorado. Most businesses were self-categorized as medical/health spas (33/93) or weight loss services (26/93). Advertised products included semaglutide (92/93), tirzepatide (40/93), liraglutide (2/93), and retatrutide (1/93). Advertised combination products included B vitamins (8/93), levocarnitine (1/93), mannitol (1/93), BPC-157 (1/93), and glycine (1/93). Seven websites advertised oral formulations. Additionally, 41/93 websites referred to Food and Drug Administration approval in their descriptions of compounded products and 5/93 referred to products as 'generic'.

Conclusion:

This study identified several instances of unapproved glucagon-like peptide-1 products being compounded and advertised in Colorado. Additionally, 1 product was advertised as compounded with BPC-157, a substance determined by the Food and Drug Administration to be unsafe for compounding. This study also identified numerous examples of misleading claims regarding the regulatory status of compounded glucagon-like peptide-1 products. Regulatory action is needed to ensure the benefits of compounded GLP-1 products outweigh the risks.

2025-12-01·Current heart failure reports

Therapeutic Potential of GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction (HFpEF) in Obese Patients

Review

作者: Patel, Ravi ; Ukah, Joan Dumebi ; Adejumo, Faith Adedayo ; Olatunji, Gbolahan ; Babalola, Adetola Emmanuel ; Ndakotsu, Andrew ; Kokori, Emmanuel ; Aderinto, Nicholas ; Abraham, Israel Charles

PURPOSE OF REVIEW:

Heart failure with preserved ejection fraction (HFpEF) is increasingly prevalent among individuals with obesity, primarily due to metabolic dysfunction and structural cardiac remodeling. This review explores the emerging therapeutic role of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in managing HFpEF in obese populations.

RECENT FINDINGS:

Recent clinical trials, including the STEP-HFpEF and SUMMIT studies, have shown that GLP-1 RAs such as semaglutide and tirzepatide significantly reduce body weight (13.3% and 13.9%, respectively), enhance exercise capacity (increases of 21.5m and 26m in 6-minute walk distance), and improve quality of life (19.5 and 16.6-point increases in KCCQ-CSS scores). Additionally, both agents demonstrated marked reductions in systemic inflammation, with C-reactive protein levels decreasing by 38.8% and 43.5%, respectively. GLP-1 RAs represent a promising class of agents targeting the cardiometabolic axis in HFpEF, offering meaningful improvements in functional capacity and symptom burden among obese patients. However, current evidence is limited by short trial durations, lack of population diversity, and insufficient long-term data. Future research should focus on more inclusive cohorts and extended outcomes such as hospitalization rates and cardiovascular events to fully define the long-term safety and efficacy of GLP-1 RAs in HFpEF management.

2,986

项与替尔泊肽相关的新闻（医药）

23 小时之前

·医药投资部落

紧追礼来！恒瑞的小分子GLP-1高歌猛进

2025年，礼来旗下的小分子GLP-1R激动剂orforglipron宣布III期临床试验成功，GLP-1类药物进入了小分子时代。相比于大分子GLP-1类药物的研发进度严重落后于国际同行，中国药企在小分子GLP-1类药物领域，进度显然要更为积极。作为国内医药界“old money”代表的恒瑞医药，近日在第85届美国糖尿病协会（ADA）大会上，公布了旗下口服GLP-1R激动剂HRS-7535的II期研究结果。该研究是一项为期36周的多中心、随机、双盲、安慰剂对照临床试验（n=235），评估了HRS-7535（30/60/120/180mg，每日1次）在不伴糖尿病的肥胖或超重（BMI：28-40kg/m2）受试者中的安全性和有效性。临床试验结果显示，在经过第26周的治疗之后，30mg剂量组、60mg剂量组、120mg剂量组、180mg 剂量组、安慰剂组受试者的体重降幅，分别达到了2.99%、7.17%、6.17%、9.36%、2.50%。治疗第36周，最高剂量的180mg剂量组，受试者的体重降幅为9.50%，而安慰剂组降幅为1.40%。在此前礼来公布的小分子GLP-1R激动剂orforglipron的III期临床试验数据中，在经过40周的治疗之后，接受最高剂量orforglipron治疗的患者，平均体重减轻16.0磅（7.9%）。虽然只是非头对头的简单数据比较，但是至少可以说明，恒瑞医药的HRS-7535，理论上具备与礼来的orforglipron一较高下的可能性。此前，由于安全性问题（主要是肝毒性），辉瑞医药接连在小分子GLP-1药物上遭遇失败，而恒瑞医药的HRS-7535此次公布的数据，显示安全性良好。具体而言，HRS-7535组最常见的不良事件为胃肠道事件，包括恶心（16.7%-54.2%）、腹泻（16.7%-21.7%）、呕吐（15.7%-37.5%），严重程度多为轻度至中度，且未观察到肝酶升高的趋势。因为不良事件而终止HRS-7535治疗的比例为2.1%，相比之下，礼来的orforglipron临床试验中，因不良事件导致的治疗中断的比例分别为6%（3 mg组）、4%（12 mg组）、8%（36 mg组）。目前，恒瑞医药已经在国内启动了HRS-7535的两项III期临床试验，分别针对降糖和减重适应症。在国际市场，HRS-7535已经完成了对外BD授权。2024年5月16日，恒瑞医药宣布，将包含HRS-7535在内的三款GLP-1类创新药的独家权利，有偿许可给美国Hercules公司。根据协议条款，美国Hercules公司将向恒瑞医药支付首付款和近期里程碑款总计1.1亿美元，临床开发及监管里程碑款累计不超过2亿美元，销售里程碑款累计不超过57.25亿美元，及达到实际年净销售额低个位数至低两位数比例的销售提成。美国Hercules公司是一家于2024年5月在美国特拉华州设立的公司，著名投资机构贝恩资本生命科学基金联合Atlas Ventures、RTW资本、Lyra资本联合出资4亿美元。2025年2月，Hercules任命礼来前高管Jamie Coleman为首席商业官，此人其曾主导Trulicity（度拉糖肽）和Zepbound（替尔泊肽减重版）的市场推广。医药研究报告分享营收集与分享全市场主流医药研究报告每天仅需0.8元畅享超过2000篇存量精选医药研究报告每年新增额外500篇

临床3期临床2期临床成功引进/卖出

23 小时之前

·同写意

监管竞速：中欧生物技术监管改革在即

同写意年度巨献！！7月25-26日，邀您相聚金鸡湖畔，与5000人一起为中国医药创新“同写意”！生物技术领域正成为全球科技竞争与经济增长的关键赛道。近期，中国与欧盟两大经济体不约而同地聚焦监管体系改革。虽改革路径并不相同，但两地目标一致：通过优化制度环境、加速研发进程、拓宽融资渠道，抢占生物经济制高点。TONACEA01中国提速新药审批，临床试验审评时间拟减半中国在生物技术领域发展迅猛，如今正计划通过缩短监管机构审查临床试验的时间，进一步加速新药研发进程。6月16日，NMPA发布政策意见稿，拟将新药的临床试验审评等待期从目前的60个工作日缩短至30个工作日。根据提案，这一30天的时限将优先适用于：中国政府支持、具有明确临床价值的重点药物；NMPA药品审评中心特定项目覆盖的儿童癌症及罕见病用药；在中国同步开展的全球研究及由中国研究者主导的国际多中心试验。这一改革的核心是采用了与FDA类似的“默认许可制”。在此机制下，若申办方在规定时限内未收到监管机构的异议通知，临床试验即可自动进行。NMPA就该新规公开征求意见至7月16日。若实施，审评时限将与FDA的30天周期看齐。此举恰逢中国生物技术产业因外资争相引进本土创新药的许可交易浪潮，而获得强劲助力。数据显示，2024年大型制药公司从中国引进的在研药物占比高达约31%，远高于2020年的10%和2015年的3%。这一趋势在2025年仍在延续。约一个月前，辉瑞达成协议，向中国三生制药支付12.5亿美元预付款，获得一款PD-1/VEGF双特异性抗体的中国以外地区权益，该药有望挑战默沙东的重磅抗癌药Keytruda。随后，再生元与中国的翰森制药签署了潜在价值20亿美元的协议，引进一款GLP-1/GIP激动剂，以追赶礼来的减肥药Zepbound。快速启动临床试验的能力，被视为中国生物技术崛起的关键驱动因素之一。前FDA局长Scott Gottlieb指出，美国公司面临的主要挑战是获得FDA I期临床批准的过程漫长且昂贵。相比之下，在中国启动人体临床试验更为简便，使本土企业能更快获得关键化合物信息，形成竞争优势。包括武田制药、GSK在内的跨国药企高管也对中国IND审批的“高速与高质量”表示惊叹。临床数据的快速生成，使得中国生物技术公司能够及早为潜在买家提供决策依据。CAR-T疗法先驱Carl June更是建议，FDA应效仿中国的监管方式，仅在疗法准备好进行更大规模、多中心试验时才介入。过去十年间，中国对临床试验的监管经历了深刻变革：2015年开始允许外国药品在国内开展国际多中心临床试验；2017年加入ICH，2018年引入60天审评制并转向默认许可制，此前新药临床试验申请的标准等待期为六个月，有时甚至超过一年。TONACEA02欧盟拟推生物技术法案，吸引投资与此同时，欧盟也正积极行动。过去二十多年，欧盟已多次承诺打造培育其生物技术领域（涵盖医疗、农业食品、海洋及工业环境技术）创新与投资的监管生态。基于当前地缘政治需求与政策优先重点，欧盟产业界与投资者正期待一系列酝酿已久的举措落地。关键支柱是拟于2026年出台的《欧盟生物技术法案》（EU Biotech Act），旨在为欧盟生物技术创新构建更敏捷、高效、顺畅的监管环境。该法案将勾勒总体愿景，使欧盟成为对产业和投资者更具吸引力的沃土，并将得到《欧洲生命科学战略》和修订版《生物经济战略》等举措支撑。法案的成功将取决于立法者能否通过简化程序的规则，并避免与现有及待定的相关法规冲突。• 《欧洲生命科学战略》（The European Life Sciences Strategy）目标是推动欧盟经济增长、韧性与安全，支持绿色和数字化转型。该战略特别聚焦产业需求，以强化欧盟竞争力。委员会近期已为此征集信息。• 修订版《生物经济战略》（A Revised Bioeconomy Strategy）将强化该战略的产业维度及与生物技术/制造的关联，以增强欧盟经济。重点应对投资生态挑战，如市场割裂、高能源成本及中小企业规模化难题。• 拟定《欧盟生物技术法案》（A Proposed EU Biotech Act）核心是为特定产品（包括难以归类者）提供简化框架和更快市场准入，提升政策清晰度与可预测性。欧盟的生物技术举措旨在抓住投资机遇。研究显示，2022年欧盟生物技术活动产生的总附加值（GVA）高达381亿欧元，是经济生产力最高的行业之一（人均GVA 16万欧元），医疗生物技术出口近年也大幅增长。除《生物技术法案》外，欧盟还提出了一系列配套举措：• 委员会2025年工作计划：包含支持创新的方案，如初创企业战略、综合法案包（Omnibus）及转基因生物（GMO）法规修订。• 加速欧盟临床试验（ACT EU）倡议：评估简化临床试验（含生物药和先进治疗药物ATMPs）评估的必要性，并寻求与美、印、日、韩等建立“生物技术和生物制造伙伴关系”。• 生物技术与生物制造中心（2025年1月启动）：为中小企业和初创公司提供法规导航及融资支持等工具。• AI融合：业界正探索利用AI精简研发和临床试验。相关行动旨在破除AI/ML在药物研发中的应用障碍，包括实施EMA的AI风险管控建议，以及修订涉及GMO的ATMPs试验法规以提供更多豁免便利。参考文章：1、EU Launches Strategic Bid to Attract R&D and Investments in Biotech；lifescience2、China proposes shorter clinical trial reviews in efforts to accelerate drug development；fiercebiotech3、重磅利好！创新药赛道再添把火；写意宣发

2025-06-16

·PRNewswire

Peptide and Anti-Aging Specialist Dr. Daniel Benhuri Now Offering Advanced Peptide Therapy, Including Semaglutide, in Beverly Hills and Los Angeles

Dr. Daniel Benhuri, a board-certified concierge physician in Beverly Hills, has introduced personalized peptide therapy to help patients optimize energy, metabolism, immunity, and recovery. The new service is available in-office or via concierge care throughout Beverly Hills and Los Angeles. BEVERLY HILLS, Calif. , June 16, 2025 /PRNewswire/ -- Dr. Daniel Benhuri, a board-certified internal medicine physician and highly rated concierge doctor in Beverly Hills, is now offering a full range of advanced peptide therapies designed to support weight loss, healing, hormone balance, sexual wellness, and cellular rejuvenation. Serving patients throughout Beverly Hills and the greater Los Angeles area, Dr. Benhuri's peptide programs now include widely requested options like Semaglutide, Tirzepatide, Tesamorelin, PT-141, BPC-157, and NAD+. Continue Reading Daniel Benhuri MD Peptides are short chains of amino acids that function as biological messengers, helping regulate metabolism, inflammation, recovery, and tissue repair. Dr. Benhuri's therapy protocols are fully customized based on labs, medical history, and patient goals—and are now available through in-office visits or concierge care across Los Angeles. "Peptide therapy is a powerful tool that allows us to treat the root causes of fatigue, weight gain, inflammation, and low libido," said Dr. Benhuri. "These are evidence-based, well-tolerated therapies that fit perfectly into our concierge wellness model. Our patients want to optimize their lives, and peptides help us deliver exactly that." Highlights of Dr. Benhuri's peptide therapy offerings include: Semaglutide and Tirzepatide (GLP-1 agonists): Support sustainable weight loss by regulating appetite and improving insulin sensitivity. Tesamorelin: Helps reduce visceral fat and promote lean muscle development. PT-141: Enhances sexual desire and performance in both men and women. BPC-157: Accelerates healing of soft tissue injuries and provides anti-inflammatory benefits. NAD+ Therapy: Though not a peptide, NAD+ is a key coenzyme used for energy metabolism, anti-aging, and cognitive enhancement. Dr. Benhuri's comprehensive programs begin with a detailed consultation and lab review. Based on individual needs, patients receive a personalized treatment plan that may include injectable peptides, nasal sprays, or topical solutions—all sourced from high-quality U.S. compounding pharmacies. Patients also benefit from ongoing clinical monitoring and adjustments as part of his concierge approach. Known for his expertise in preventive care, weight management, and regenerative medicine, Dr. Benhuri offers these new services as a natural extension of his commitment to helping patients feel better, function better, and age with confidence. More About Dr. Daniel Benhuri Dr. Daniel Benhuri is a highly respected internal medicine and primary care physician serving patients in Beverly Hills and the surrounding areas. He offers a vast array of services, including advanced diagnostic imaging, executive physicals, medical weight loss plans, preventive care, and aesthetic treatments. By integrating concierge care and cutting-edge technology, Dr. Benhuri delivers an unmatched level of patient-focused care. His practice is located at 9400 Brighton Way, Suite 210, Beverly Hills, CA 90210. For more information or to schedule an appointment, visit or call (310) 362-1255. Media Contact Dr. Daniel Benhuri (310) 362-1255 SOURCE Daniel Benhuri M.D. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 项与替尔泊肽相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11360	替尔泊肽	-	DB15171

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
阻塞性睡眠呼吸暂停综合征	美国	Eli Lilly & Co.	2024-12-20
肥胖	美国	Eli Lilly & Co.	2023-11-08
超重	美国	Eli Lilly & Co.	2023-11-08
体重增加	澳大利亚	Eli Lilly Australia Pty Ltd.	2022-12-23
2型糖尿病	美国	Eli Lilly & Co.	2022-05-13

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
射血分数保留型心力衰竭	申请上市	中国	Eli Lilly & Co.	2024-11-22
肥胖通气不足综合征	申请上市	中国	Eli Lilly & Co.	2024-09-15
溃疡性结肠炎	临床3期	美国	Eli Lilly & Co.	2025-06-01
溃疡性结肠炎	临床3期	奥地利	Eli Lilly & Co.	2025-06-01
溃疡性结肠炎	临床3期	比利时	Eli Lilly & Co.	2025-06-01
溃疡性结肠炎	临床3期	巴西	Eli Lilly & Co.	2025-06-01
溃疡性结肠炎	临床3期	加拿大	Eli Lilly & Co.	2025-06-01
溃疡性结肠炎	临床3期	克罗地亚	Eli Lilly & Co.	2025-06-01
溃疡性结肠炎	临床3期	捷克	Eli Lilly & Co.	2025-06-01
溃疡性结肠炎	临床3期	丹麦	Eli Lilly & Co.	2025-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2025	N/A	肿瘤	-	Tirzepatide	鏇鏇衊衊齋鹽獵築鏇獵(壓鏇願鹽蓋鹽蓋夢鏇夢) = 繭齋夢製顧夢糧衊艱繭繭餘夢遞壓鹽憲淵遞願 (願鑰膚壓網窪範製製積 )	积极	2025-05-30
				GLP-1 receptor agonists	鏇鏇衊衊齋鹽獵築鏇獵(壓鏇願鹽蓋鹽蓋夢鏇夢) = 夢簾願壓範觸鑰餘鏇餘繭餘夢遞壓鹽憲淵遞願 (願鑰膚壓網窪範製製積 )
NCT05822830 (SURMOUNT-5, Pubmed \| N Engl J Med) 人工标引	临床3期	肥胖	751	TirzepatideTirzepatide 10 mg or 15 mg	獵憲選壓獵艱願壓艱艱(艱壓遞鑰壓鑰構夢夢醖) = 願鬱範獵壓襯餘鹹積製餘衊獵醖夢膚糧觸網鹹 (獵觸選製繭鬱積繭網廠, -21.4 ~ -19.1) 更多	积极	2025-05-11
				Semaglutide Semaglutide 1.7 mg or 2.4 mg	獵憲選壓獵艱願壓艱艱(艱壓遞鑰壓鑰構夢夢醖) = 餘選餘簾築艱選齋窪築餘衊獵醖夢膚糧觸網鹹 (獵觸選製繭鬱積繭網廠, -14.9 ~ -12.6) 更多
NCT05564039 (SURPASS-SWITCH, Pubmed \| Ann Intern Med)	临床4期	-	282	Tirzepatide	艱膚製繭廠範觸壓鏇襯(簾膚範範糧鏇製齋壓蓋) = 網衊簾夢遞蓋遞構窪繭製襯憲醖鏇餘襯膚餘顧 (遞網製願製積鹽鑰蓋鑰, 0.07) 更多	积极	2025-05-01
				Dulaglutide	艱膚製繭廠範觸壓鏇襯(簾膚範範糧鏇製齋壓蓋) = 艱獵夢鹽築壓膚範憲糧製襯憲醖鏇餘襯膚餘顧 (遞網製願製積鹽鑰蓋鑰, 0.08) 更多
NCT05412004 (SURMOUNT-OSA, CTgov)	临床3期	阻塞性睡眠呼吸暂停综合征 \| 肥胖	469	Tirzepatide (Tirzepatide MTD_GPI1)	獵選膚鹹網製繭觸網繭(壓築淵蓋憲網蓋餘蓋壓) = 淵獵積鹹衊願觸夢構願醖網壓遞齋壓憲製壓願 (衊願憲觸鬱遞築餘獵艱, 2.06) 更多	-	2025-04-30
				Placebo (Placebo_GPI1)	獵選膚鹹網製繭觸網繭(壓築淵蓋憲網蓋餘蓋壓) = 鏇製遞餘鹽餘觸窪築簾醖網壓遞齋壓憲製壓願 (衊願憲觸鬱遞築餘獵艱, 2.11) 更多
NCT05978713 (CTgov)	临床1期	-	11	Tirzepatide	網製鏇製獵製選遞餘餘(繭積範選網窪鬱鏇淵遞) = 願襯獵醖選鬱膚艱鑰鏇觸繭鬱願獵範繭夢構鹹 (糧積蓋鬱衊蓋淵範網積, NA) 更多	-	2025-04-27
S30.005 (AAN2025)	N/A	2型糖尿病	-	Tirzepatide	襯醖願淵淵遞廠鬱鑰餘(夢餘範艱蓋廠簾觸憲鑰): HR = 1.18 (95% CI, 1.07 ~ 1.29) 更多	积极	2025-04-07
				Semaglutide
NCT04847557 (Pubmed \| Circulation)	临床3期	舒张期心力衰竭	731	Tirzepatide	鏇鏇積製齋選憲膚鏇憲(積繭簾襯壓糧繭艱獵獵) = 壓鏇餘獵製夢製範齋壓鹹鹹願觸鬱遞壓繭鹹鹽 (窪糧窪願艱鏇夢蓋醖膚 )	积极	2025-03-11
NCT03861052 (SURPASS J-mono, Pubmed \| Diabetes Ther)	临床3期	2型糖尿病 C-peptide	636	Tirzepatide 5 mg	齋鏇憲廠顧觸築壓艱願(鬱鑰鏇壓顧鬱艱積衊鬱) = 築艱築構鹽鹽製鑰鏇鹹鏇鑰蓋鹽襯積窪鬱築繭 (廠獵齋淵範獵築觸觸鏇 ) 更多	积极	2025-02-14
				Tirzepatide 10 mg	齋鏇憲廠顧觸築壓艱願(鬱鑰鏇壓顧鬱艱積衊鬱) = 夢簾鏇顧積糧糧構鏇網鏇鑰蓋鹽襯積窪鬱築繭 (廠獵齋淵範獵築觸觸鏇 ) 更多
NCT04166773 (SYNERGY-NASH, CTgov)	临床2期	非酒精性脂肪性肝炎	190	Tirzepatide (5 mg Tirzepatide)	鏇網鬱鏇窪齋顧襯壓齋 = 築廠積築鹽獵糧齋簾淵觸製齋壓鬱顧窪憲網遞 (餘壓襯醖鹽憲襯襯窪鏇, 鏇憲範範淵築鏇積觸願 ~ 築獵願醖鹽衊鏇選顧齋) 更多	-	2025-01-24
				Tirzepatide (10 mg Tirzepatide)	鏇網鬱鏇窪齋顧襯壓齋 = 鹽淵廠窪網糧製範憲獵觸製齋壓鬱顧窪憲網遞 (餘壓襯醖鹽憲襯襯窪鏇, 艱顧醖鹹齋繭簾蓋積壓 ~ 網醖積築簾餘醖壓築醖) 更多
Pubmed 人工标引	N/A	超重 \| 肥胖	15,491	Tirzepatide 15 mg once weekly	蓋憲膚鏇網鬱積築簾憲(膚鑰壓鏇鬱夢鑰遞顧醖) = 憲獵繭齋膚糧廠鹹齋齋壓醖餘構醖鏇鬱鹽艱窪 (積衊壓獵構鹽構網遞艱 )	积极	2025-01-07
				Semaglutide 2.4 mg once weekly	蓋憲膚鏇網鬱積築簾憲(膚鑰壓鏇鬱夢鑰遞顧醖) = 觸衊鏇鑰膚築鬱築襯醖壓醖餘構醖鏇鬱鹽艱窪 (積衊壓獵構鹽構網遞艱 )